Lower Prices, Bigger Market: The Next Phase of GLP-1 Drugs

Summary

Morgan Stanley analysts discuss the global GLP-1 obesity drug market, focusing on the impact of early semaglutide generics in India, Canada and Brazil, which could preview US and European dynamics. They highlight tirzepatide's differentiation and premium pricing power, oral GLP-1s driving market expansion, and the near-term catalyst of US Medicare coverage for obesity drugs. Supply chain risks in fill and finish and ongoing pipeline innovation are also covered.

• Semaglutide generics launched in India, Canada and Brazil, with India seeing 6x volume surge and value expected to hit >$1B by 2030.
• Chinese API suppliers are building multi-ton capacity, removing API bottlenecks; device supply is also adequate, but fill and finish capacity may tighten.
• Tirzepatide's dual-pathway action delivers better efficacy and tolerability, supporting premium pricing and market share gains vs generics.
• Oral GLP-1s are expanding the US market, with most users being new to the category.
• Non-peptide oral GLP-1s offer easier scalability, a variable to monitor for future capacity.
• US Medicare coverage for obesity drugs at $50/month begins this summer, unlocking 18 million additional patients.
• Pipeline innovation focuses on monthly injections and new targets like amylin and glucagon.